110 related articles for article (PubMed ID: 16898492)
1. [Osteoprotegerin and calcium-phosphorus metabolism parameters in children with chronic renal failure].
Ziółkowska H; Roszkowska-Blaim M
Przegl Lek; 2006; 63 Suppl 3():68-71. PubMed ID: 16898492
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostic value of PTH total kit for estimation of bone turnover in children with chronic renal failure].
Ziółkowska H; Roszkowska-Blaim M
Przegl Lek; 2006; 63 Suppl 3():149-52. PubMed ID: 16898516
[TBL] [Abstract][Full Text] [Related]
3. [Serum osteocalcin in children with chronic renal insufficiency].
Peco-Antić A; Nastić-Mirić D; Milikić V; Babić D; Pejcić I; Kostić M; Paripović V; Jovanović O; Kruscić D; Mancić J
Srp Arh Celok Lek; 1996; 124(9-10):227-31. PubMed ID: 9102853
[TBL] [Abstract][Full Text] [Related]
4. Serum osteoprotegerin (OPG) in children with primary nephrotic syndrome.
Mohamed GB; Abdel-Latif EA
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):955-62. PubMed ID: 21912025
[TBL] [Abstract][Full Text] [Related]
5. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
[TBL] [Abstract][Full Text] [Related]
6. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
7. Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease.
Grzegorzewska AE; Młot M
Rocz Akad Med Bialymst; 2004; 49():190-2. PubMed ID: 15631341
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels of osteoprotegerin and receptor activator of NF-kappaB ligand in patients with chronic renal failure.
Shaarawy M; Fathy SA; Mehany NL; Hindy OW
Clin Chem Lab Med; 2007; 45(11):1498-503. PubMed ID: 17970704
[TBL] [Abstract][Full Text] [Related]
9. [CIP and CAP fragments of parathormone and selected parameters of calcium-phosphate balance in patients with chronic kidney disease treated with repeated haemodialysis].
Polak-Jonkisz D; Zwolińska D; Nahaczewska W
Pediatr Endocrinol Diabetes Metab; 2010; 16(1):25-8. PubMed ID: 20529602
[TBL] [Abstract][Full Text] [Related]
10. Circulating osteoprotegerin is associated with age and systolic blood pressure, but not with lipid profile or fasting glucose, in postmenopausal women.
Uemura H; Yasui T; Miyatani Y; Yamada M; Hiyoshi M; Arisawa K; Irahara M
Menopause; 2008; 15(1):180-4. PubMed ID: 17545921
[TBL] [Abstract][Full Text] [Related]
11. Effect of L-carnitine supplementation on secondary hyperparathyroidism and bone metabolism in hemodialyzed patients.
Cibulka R; Racek J; Pikner R; Rajdl D; Trefil L; Vesela E; Studenovska M; Siroka R
Calcif Tissue Int; 2007 Aug; 81(2):99-106. PubMed ID: 17622482
[TBL] [Abstract][Full Text] [Related]
12. [Fetuin A in children with renal diseases].
Ziółkowska H; Wojnar J; Pańczyk-Tomaszewska M; Roszkowska-Blaim M
Przegl Lek; 2006; 63 Suppl 3():54-6. PubMed ID: 16898488
[TBL] [Abstract][Full Text] [Related]
13. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay of carboxyl and amino terminal fragments of parathyroid hormone for the evaluation of secondary hyperparathyroidism in chronic renal failure.
Zanella MT; Silva MC; Peres RB; Ferreira SR; Draibe SA; Vieira JG
Braz J Med Biol Res; 1990; 23(3-4):235-43. PubMed ID: 2094538
[TBL] [Abstract][Full Text] [Related]
15. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
[TBL] [Abstract][Full Text] [Related]
16. [Serum osteoprotegerin level in children with nephrotic syndrome and the effect of glucocorticoid on it].
Li YL; Wang H
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Sep; 14(9):653-6. PubMed ID: 22989431
[TBL] [Abstract][Full Text] [Related]
17. High serum osteoprotegerin levels in patients with hyperthyroidism: effect of medical treatment.
Amato G; Mazziotti G; Sorvillo F; Piscopo M; Lalli E; Biondi B; Iorio S; Molinari A; Giustina A; Carella C
Bone; 2004 Sep; 35(3):785-91. PubMed ID: 15336617
[TBL] [Abstract][Full Text] [Related]
18. [Phosphorus and calcium metabolism and its hormonal regulation in chronic kidney failure].
Nikiforova NV; Strunin SE; Ermolenko VM; Mozzhechkov VT; Khomiakova VN
Ter Arkh; 1985; 57(1):103-7. PubMed ID: 3983831
[TBL] [Abstract][Full Text] [Related]
19. Association between phosphate removal and markers of bone turnover in haemodialysis patients.
Albalate M; de la Piedra C; Fernández C; Lefort M; Santana H; Hernando P; Hernández J; Caramelo C
Nephrol Dial Transplant; 2006 Jun; 21(6):1626-32. PubMed ID: 16490746
[TBL] [Abstract][Full Text] [Related]
20. Relationships between serum osteoprotegerin, matrix metalloproteinase-2 levels and bone metabolism in postmenopausal women.
Dai Y; Shen L
Chin Med J (Engl); 2007 Nov; 120(22):2017-21. PubMed ID: 18067789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
